Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · Virtus

Virtus Biotech ETF (BBP)

Ticker BBP · · Holdings as of Jul 31, 2026

Expense ratio
0.34%$34/yr per $10k
5-yr return
+8.4%annualized
1-yr return
+32.8%as of Dec 2025
Net assets
$98.5Mall share classes
Holdings
70

Bottom line

Is BBP a good fund? The bottom line

BBP is an actively managed technology sector ETF from Virtus.

It charges 0.34% — about $34 a year on every $10,000 invested, cheaper than 94% of technology sector funds we track.

It returned +32.8% over one year, +8.4% a year over five years, +10.0% a year over ten (as of Dec 31, 2025, per its prospectus).

With $98.5 million in net assets and 70 holdings, its largest position is Crinetics Pharmaceuticals Inc (3.3%) and the top 10 make up 19.6% of the portfolio.

What stands out

  • Low cost: cheaper than 94% of technology sector peers

Updated Nov 19, 2026

What BBP invests in

The Virtus Biotech ETF (formerly,Virtus LifeSci Biotech Products ETF) (the Fund ) seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index (the Underlying Index ).

Under normal market conditions, the Fund will invest not less than 80% of its assets in component securities of the Underlying Index. The Underlying Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ( FDA ) for marketing. The Underlying Index is sponsored by LifeSci Index Partners, LLC (the Index Provider ). The Index Provider utilizes a selection committee comprised of its employees (the Index Committee ) that is responsible, pursuant to the rules included in the methodology for the Underlying Index, for making certain determinations for the Underlying Index, as more fully described below. The Index Committee utilizes various public data sources to make determinations, including, but not limited to, Securities and Exchange Commission ( SEC ) filings…

From the fund's prospectus (filed Feb 27, 2026).

BBP performance

Fund calendar-year total returns, 2016–2025 2016: +6.5%; 2017: +23.8%; 2018: −13.8%; 2019: +24.9%; 2020: +22.2%; 2021: −8.2%; 2022: +1.0%; 2023: +17.4%; 2024: +3.6%; 2025: +32.8% +6% 2016 +24% 2017 −14% 2018 +25% 2019 +22% 2020 −8% 2021 +1% 2022 +17% 2023 +4% 2024 +33% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BBP+32.8%+8.4%+10.0%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full BBP performance history →

What BBP costs

On a $10,000 investment, BBP's 0.34% expense ratio costs about $34 a year. The prospectus estimates $431 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full BBP fee table →

BBP top 10 holdings

#Holding% of fund
1Crinetics Pharmaceuticals Inc CRNX3.34%
2Kiniksa Pharmaceuticals International Plc KNSA1.97%
3Verastem Inc VSTM1.95%
4Precigen Inc PGEN1.94%
5Omeros Corp OMER1.87%
6Nuvation Bio Inc NUVB1.77%
7Regeneron Pharmaceuticals REGN1.72%
8Protagonist Therapeutics Inc PTGX1.71%
9Acadia Pharmaceuticals Inc ACAD1.69%
10Bridgebio Pharma Inc BBIO1.65%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 19.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to BBP

More funds like BBP →

BBP FAQ

What is the expense ratio of BBP?
BBP's expense ratio is 0.34%, which works out to about $34 a year for every $10,000 invested. The prospectus estimates total costs of $431 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BBP a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 94% of technology sector peers. This is general information, not personalized advice.
What does BBP hold?
BBP's largest holdings are Crinetics Pharmaceuticals Inc (3.3%), Kiniksa Pharmaceuticals International Plc (2.0%), Verastem Inc (1.9%), Precigen Inc (1.9%), Omeros Corp (1.9%). It holds 70 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is BBP's 5-year return?
BBP returned +8.4% a year over the five years ending Dec 31, 2025, and +10.0% a year over ten years. Past performance does not guarantee future results.
Who manages BBP?
BBP is offered by Virtus through ETFis Series Trust I.